Short answer
Travere Therapeutics, Inc. (TVTX) filed an 8-K current report with the SEC on July 9, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). CAO/PAO Sandra Calvin plans retirement after expected February 2027 Form 10-K filing.
Travere Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CAO/PAO Sandra Calvin plans retirement after expected February 2027 Form 10-K filing
- Vice President, Controller John Torell expected successor, supporting continuity in financial reporting
- Board appointment anticipated before retirement to enable orderly transition
- Torell’s experience includes SEC reporting, internal controls, CPA and CFA credentials
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Travere Therapeutics, Inc. 8-K filings
Get the next TVTX 8-K as it lands
Follow TVTX for push alerts, or ask the research agent what this filing means.